Jessica Merrill
Senior Editor
Latest From Jessica Merrill
Blueprint’s Evolution On Its Path To Financial Sustainability
Chief operating officer Christina Rossi talked to Scrip about the company’s new blockbuster-sized commercial opportunity for Ayvakit and the company’s next phase: financial sustainability.
Jardiance Improves Double-Digit Growth Potential With US Approval In CKD
Boehringer expects Jardiance’s new chronic kidney disease indication to keep its sales growing by double-digit percentages over the coming years, aided by the drug’s ability to reduce hospitalizations.
Administrative Burden, Class-Wide Impacts Are Among IRA Pitfalls
As Medicare drug price negotiations creep closer to reality, industry leaders are turning attention to the challenges of implementation and commercial concerns.
BioMarin’s Next Chapter: ‘A Financial Growth Story’
The company presented its pipeline to investors during an R&D day, outlining expansion plans for Voxzogo and Roctavian as well as several early pipeline drugs.
Amgen’s Plan To Go Big In Obesity
Competing in the obesity market will require significant investment, which Amgen is preparing for, CEO Robert Bradway told investors during the Morgan Stanley Healthcare conference.
Seagen And Nurix Hope To Pioneer A New Class Of Degrader-Antibody Conjugates
The two drug developers announced a collaboration to develop and commercialize multiple cancer programs. Nurix will receive $60m up front.